Pharmaceutical News

Acacia Pharma is a pharmaceutical company focused on supportive care products for use in hospitals. Acacia Pharma specialises in cancer supportive care, a rapidly developing commercial opportunity. The growth in the cancer supportive care market is driven by the expansion of effective cancer therapies and the desire to improve both the effectiveness of treatment and the quality of life of cancer patients. Acacia Pharma has developed a pipeline of drug candidates addressing a number of supportive care indications using its lower-risk commercially driven approach to new product discovery. The Company’s lead product, APD 405, for the treatment of nausea and vomiting, is due to enter Phase I clinical studies shortly. Acacia is developing products for additional indications such as cancer fatigue and cancer cachexia. Acacia products are expected to reach the market quickly given that they are based on the novel use of well-characterised pharmaceuticals. Acacia Pharma, which was founded in 2007, is led by an experienced management team who have already successfully built and exited a number of life sciences companies. Management and Gilde Healthcare are the Company’s key shareholders. Acacia Pharma is based in Cambridge, UK.